title: [How to avoid a haemotransfusion which is not lifesaving? (our experience with administration of intravenous iron to pregnant women and young mothers)].
abstract: OBJECTIVE
  To study the effect of intravenous administration of the iron-containing medicine Venofer to pregnant women and young mothers with anaemic syndrome.
  
  
  METHODS
  A 2-year prospective study was conducted to 50 pregnant women and young mothers, which were treated for iron deficiency anemia in First Obstetrical Clinic of University Hospital - Pleven. There were 27 pregnant women (gestational age 24-39 g. w.) and 23 young mothers. A treatment with Venofer was conducted following 5 ampules regimen of administration--1st day 3 amps and 2d day--2 amps. Venofer is a stabile iron-sucrose complex designed for intravenous application. It is a structural analogue of feritine. Control studies of haemoglobin (Hb) and erythrocytes (Er) were made on 6-7 day after the therapy.
  
  
  CONCLUSIONS
  The pregnant women had average starting Hb-data of 90.74 g/l and after the therapy--106.19 g/l. The increase was of 15.74 g/l. Young mothers had Hb-data before the therapy 88.04 g/l and after the therapy 104.5 g/l. The mean increase of Hb was of 16.46 g/l. Undesired side reactions were observed only in one pregnant woman and that necessitated the stop of therapy. Intravenous administration of iron contributed to the good, normal course of pregnancy and fetal growth, and the effect to young mothers consisted of quick and certain recovery of their general state without accomplishing haemotransfusion.
  
  
  CONCLUSIONS
  Therapy with iron-containing medicine gives a good opportunity to avoid the risk of haemotransfusional infections, incopatible haemotransfusions and immunocompromizing effect of allogene haemotransfusion. It is also economically more beneficial.
authors.forename: S
authors.initials: S
authors.lastname: Bozhinova
authors.forename: I
authors.initials: I
authors.lastname: Ivanova
authors.forename: M
authors.initials: M
authors.lastname: Lukanova
mesh_terms: D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy*; D001803:Blood Transfusion; D004334:Drug Administration Schedule; D004906:Erythrocyte Count; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D000077605:Ferric Oxide, Saccharated; D005865:Gestational Age; D005937:Glucaric Acid; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007275:Injections, Intravenous; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood / Q000188:drug therapy*; D011256:Pregnancy Outcome; D011446:Prospective Studies; D013395:Sucrose / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D005290:Ferric Compounds; D006454:Hemoglobins; D013395:Sucrose; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid